Investigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.
David Ziegler, MD, PhD, discusses findings from the phase 2 FIREFLY-1 trial of tovorafenib in pediatric patients with low-grade glioma.
Wade T. Iams, MD, discusses the impact of adagrasib on the treatment of patients with KRAS G12C-mutant NSCLC in the second line, as well as its integration into clinical practice.
Samuel Ahuno discusses bringing precision medicine in cancer care to Ghana.
Ashish Manne, MBBS, discusses the need to develop novel therapies for patients with hepatocellular carcinoma without preserved liver function.
Raymond Mailhot Vega, MD, MPH, discusses the efficacy of axillary surgery in patients with breast cancer previously given neoadjuvant chemotherapy, according to findings from a retrospective analysis.
Closing out her discussion on HER2+ metastatic breast cancer, Cynthia Lynch, MD, shares her excitement for treatment strategies in the setting of brain metastases.
Fredrik Schjesvold, MD, PhD, discusses key takeaways from the phase 3 OCEAN trial that was done in patients with relapsed/refractory multiple myeloma.
Timothy M. Pawlik, MD, PhD, MPH, discusses advances in the management of patients with metastatic colorectal cancer with liver metastases.
Wrapping up their discussion, Loretta J. Nastoupil, MD, and Marc S. Hoffman, MD, look at the use of CAR T-cell therapy for patients with mantle cell lymphoma, a rare subtype of non-Hodgkin’s lymphoma.
Gloria Marquina, MD, PhD, as well as the need to consider ongoing clinical trials for patients with gastrointestinal stromal tumors vs treatment with the current second-line standard-of-care agent sunitinib.
Pere Barba, MD, PhD, discusses the safety of obecabtagene autoleucel in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Diana Sutherland, NP, discusses the promise of CDK4 inhibitors in patients with metastatic breast cancer.
Akriti Jain, MD, discusses the phase 1b VERONA study of venetoclax plus azacitidine in higher-risk myelodysplastic syndromes.
Clinical pearls regarding ways to integrate antibody-drug conjugates into treatment algorithms when managing patients with breast cancer.
A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.
Gary Gibbon, MD, pulmonologist and allergist, visited Chicago for a first-of-its-kind transplant procedure, becoming the first person in the U.S. to receive a double-lung and liver transplant for advanced lung cancer.
Ivan Marazzi, PhD, discusses the goals for examining topotecan as a treatment for patients with COVID-19 and cancer in India and Brazil.
In this review, authors highlight multidisciplinary treatment for patients with advanced disease, and integrating systemic therapy options with surgery and radiation therapy.
Bruno B. Bockorny, MD, discusses findings from a phase 1a/b trial with the combination of botensilimab and balstilimab in patients with recurrent platinum-refractory or platinum-resistant ovarian cancer.
Amy L. Cummings, MD, PhD, discusses key findings from the phase 3 ADAURA trial in patients with non–small cell lung cancer harboring EGFR mutations.
Jing-Yi Chern, MD, ScM, discusses outcomes with PARP inhibitors in patients with recurrent ovarian cancer.
Mary F. Mulcahy, MD, discusses the design of the phase 3 EPOCH trial in patients with metastatic colorectal cancer and liver metastases.
Amir Fathi, MD, discusses findings from the phase 1b expansion portion of the phase 1/2 KOMET-001 trial in patients with relapsed/refractory acute myeloid leukemia harboring NPM1 mutations.
Pebbles Fagan, Ph.D., MPH, has assumed the role of associate director for Cancer Prevention and Control for the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences.
Marilena Tauro, PhD, discusses the investigation of ULK3 in patients with multiple myeloma.
Following its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.
As more and more people in the United States identify as lesbian, gay, bisexual, transgender, queer, intersex, or other sexual orientation or gender minority, the population of LGBTQI+ cancer survivors is becoming uniquely heterogeneous.